Alimentary Pharmacology & Therapeutics

CymaBay Announces Publication of Two-year Safety and Efficacy Results of Seladelpar in Patients with Primary Biliary Cholangitis

Retrieved on: 
Wednesday, November 1, 2023
McWherter, Liver injury, Patient, University of Texas Southwestern Medical Center, AST, MD, Conditional sentence, Liver, Professor, ALP, PBC, Bilirubin, Vierling, Alkaline phosphatase, Cholestasis, Primary biliary cholangitis, University, Safety, Alimentary Pharmacology & Therapeutics, Therapy, ALT, Diagnosis, Liver disease, Pharmaceutical industry, DA, RJ, Y, PJ

Patients with PBC were eligible to enroll in this long-term extension study if they had successfully completed a prior study of seladelpar.

Key Points: 
  • Patients with PBC were eligible to enroll in this long-term extension study if they had successfully completed a prior study of seladelpar.
  • The objectives were to evaluate the long-term safety, tolerability, and efficacy of seladelpar at 5 mg and 10 mg once daily throughout 2-years.
  • In addition, ALP normalization was achieved in 23% and 42% in patients at one and two years, respectively.
  • In the study long-term treatment with seladelpar resulted in continued improvement in markers of cholestasis and liver injury in the second year of treatment.

Mindset Health raises US$12m to expand digital hypnotherapy apps & scale distribution

Retrieved on: 
Tuesday, March 21, 2023
Systematic review, Ten Mile, Mindset Network, Depression, Nociception, Mouth, Habit, Nicotine, WordPress, Motility, Menopause, Anxiety, Irritable bowel syndrome, Sleep, Monash University, Health, Smoking cessation, Research, Multimedia, Meta-analysis, Linktree, Hot, Complementary Therapies in Medicine, Mindset, Neuroscience & Biobehavioral Reviews, Abdominal pain, Baylor University, Partner, Investment, Patient, IBS, Smartphone, Complement, Randomized controlled trial, Immune system, Hypnosis, Growth, Chronic pain, Smoking, Alimentary Pharmacology & Therapeutics, Cryptocurrency, Medical device, Nursing, Dietary supplement, Management, Online shopping, Automattic, Medicine

MELBOURNE, Australia, March 21, 2023 /PRNewswire/ -- Mindset Health, the digital hypnotherapy company, today announced it has raised US$12 (A$17.8) million in an oversubscribed Series A financing led by King River Capital, the leading US, Australian VC investor, with investments from Tatterang's Tenmile, Yard Ventures, Matt Mullenweg (founder of Automattic, Wordpress), John Kim (founder of SendBird), Alex and Anthony Zaccaria/Nick Humphreys (Linktree founders), Sandy Kory, Banana Capital and others

Key Points: 
  • The apps help people manage a range of health conditions anytime, anywhere.
  • Mindset Health currently has three hypnotherapy apps, addressing medically-diagnosed irritable bowel syndrome, menopause and smoking cessation.
  • Mindset Health is also looking to significantly scale up its team, with requirements across all aspects of the business, from software engineering to healthcare sales.
  • Making a difference is important to us as a collective and we're keen to encourage more like-minded people to join Mindset Health.

Galectin Therapeutics contribution to improve histology interpretation of cirrhotic liver biopsies with Machine Learning published in prominent Gastroenterology Journal

Retrieved on: 
Tuesday, January 24, 2023
Machine learning, Pharmacology, Fibrosis, Liver, Indiana University School of Medicine, Cirrhosis, Alimentary Pharmacology & Therapeutics, Hepatology, Division, Therapy, NASH, Houston Methodist Hospital, Patient, GALT, Gastroenterology (journal), Histology, Medical device, Gastroenterology

NORCROSS, Ga., Jan. 24, 2023 (GLOBE NEWSWIRE) -- Galectin Therapeutics Inc. (NASDAQ:GALT), the leading developer of therapeutics that target galectin proteins, today announced that the scientific paper, “Machine Learning Liver Histology Scores Correlate With Portal Hypertension Assessments In Nonalcoholic Steatohepatitis Cirrhosis,” was published in Alimentary Pharmacology and Therapeutics, a prominent peer-reviewed gastroenterology journal.

Key Points: 
  • NORCROSS, Ga., Jan. 24, 2023 (GLOBE NEWSWIRE) -- Galectin Therapeutics Inc. (NASDAQ:GALT), the leading developer of therapeutics that target galectin proteins, today announced that the scientific paper, “Machine Learning Liver Histology Scores Correlate With Portal Hypertension Assessments In Nonalcoholic Steatohepatitis Cirrhosis,” was published in Alimentary Pharmacology and Therapeutics, a prominent peer-reviewed gastroenterology journal.
  • The study was done in collaboration with key U.S. academic hepatology centers and with HistoIndex Pte Ltd of Singapore.
  • The study explored liver slides from patients with portal hypertension caused by NASH liver cirrhosis.
  • Data were acquired by a proprietary second harmonic generation/two-photon excitation fluorescence system and submitted to a machine learning-based analysis.

Can-Fite to Conduct Investor Meetings during the J.P. Morgan Healthcare Conference

Retrieved on: 
Monday, January 10, 2022
Research, FDA, Diabetes, Clinical Trials, Biotechnology, Health, Pharmaceutical, Science, Oncology, Liver cancer, Gastroenterology, SEC, NAFLD, TASE, Inflammation, Erectile dysfunction, Colon, Hepatocellular carcinoma, Drug development, European Medicines Agency, Melanoma, Industry, Liver, Cancer, Patient, Institute of Liver and Biliary Sciences, New Drug Application, Psoriasis, Conference, CANF, A3, NDA, HCC, Forward-looking statement, U.S. Securities and Exchange Commission, Cirrhosis, Food, NYSE, Company, Prostate, Non-alcoholic fatty liver disease, Risk, Alimentary Pharmacology & Therapeutics, Technology, Fatty liver disease, NASH, AP, COVID-19, FDA, Patisiran, EMA, Writing, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Pharmaceutical industry, Namodenoson, Can-Fite BioPharma Ltd., NAMODENOSON, CAN-FITE BIOPHARMA LTD.

(NYSE American: CANF) (TASE: CFBI), a biotechnology company with a pipeline of proprietary small molecule drugs that address inflammatory and liver diseases, announced today that it will hold one-on-one virtual investor meetings during the J.P. Morgan Healthcare Conference.

Key Points: 
  • (NYSE American: CANF) (TASE: CFBI), a biotechnology company with a pipeline of proprietary small molecule drugs that address inflammatory and liver diseases, announced today that it will hold one-on-one virtual investor meetings during the J.P. Morgan Healthcare Conference.
  • According to AP&T, the article was the top electronic download in the month of November of articles published in AP&T.
  • Both the U.S. Food and Drug Administration (FDA) and European Medicines Agency (EMA) have agreed with the design of the 471-patient study.
  • Namodenoson is a small orally bioavailable drug that binds with high affinity and selectivity to the A3 adenosine receptor (A3AR).

VBI Vaccines Announces Dosing of First Patient in Second Phase 2 Study in Chronic Hepatitis B Patients as Part of Expansion of Clinical Collaboration With Brii Bio

Retrieved on: 
Wednesday, January 5, 2022
Research, Infectious Diseases, FDA, Clinical Trials, Other Health, Biotechnology, Pharmaceutical, Health, Science, Oncology, Vaccine, Therapy, COVID-19, Trial of the century, Data monitoring committee, Hepatitis B, HBsAg, Research, Company, Patient, Liver cancer, Immune system, Sirna, CMV, VBI, Patient safety, Infection, Cytomegalovirus, Pharmacology, Hepatocellular carcinoma, HBV, Annual report, C1-inhibitor, Private Securities Litigation Reform Act, Liver disease, Disease, CEO, SEC, Alimentary Pharmacology & Therapeutics, Virus, Achievement, Safety, Systematic review, Glioblastoma, Nasdaq, GBM, Industry, Meta-analysis, VLP, Nature, Pharmaceutical industry, the Phase 2a/2b Study, VBI Vaccines Inc., THE PHASE 2A/2B STUDY, VBI VACCINES INC.

Our commitment to the fight against hepatitis B includes a focus on both prevention and treatment of the disease, said Jeff Baxter, VBIs President and CEO.

Key Points: 
  • Our commitment to the fight against hepatitis B includes a focus on both prevention and treatment of the disease, said Jeff Baxter, VBIs President and CEO.
  • Brii Biosciences (Brii Bio) is the sponsor of this newly announced Phase 2a/2b study and, with the support of VBI, has led the design and implementation of this study as well as the ongoing Phase 2 combination study.
  • Brii Bio licensed commercial rights to VBI-2601 (BRII-179) in China, Hong Kong, Macau, and Taiwan from VBI Vaccines in December of 2018.
  • Systematic review with meta-analysis: combination treatment of regimens based on pegylated interferon for chronic hepatitis B focusing on hepatitis B surface antigen clearance.

Can-Fite Reports Third Quarter 2021 Financial Results & Provides Clinical Update

Retrieved on: 
Friday, November 26, 2021
Biotechnology, Pharmaceutical, Health, Clinical Trials, CANF, Patient, Research, Institute of Liver and Biliary Sciences, Liver disease, Insurance, Safety, Psoriasis, Alimentary Pharmacology & Therapeutics, Cytokine release syndrome, Company, American Association for the Study of Liver Diseases, Use, NYSE, Exercise, Rheumatoid arthritis, Cancer, Diagnosis, Liver, AASLD, COVID-19, Corporation, Liver cancer, Public relations, Treatment, Investment, Non-alcoholic fatty liver disease, Hepatocellular carcinoma, Patent, Steatohepatitis, NASH, HCC, Therapy, American Association, Association, National Core Indicators, Gastroenterology, TASE, IP, Pharmaceutical industry, Medical device, Cryptocurrency

(NYSE American: CANF) (TASE: CFBI), a biotechnology company advancing a pipeline of proprietary small molecule drugs that address inflammatory, cancer and liver diseases, today announced financial results for the quarter ended September 30, 2021.

Key Points: 
  • (NYSE American: CANF) (TASE: CFBI), a biotechnology company advancing a pipeline of proprietary small molecule drugs that address inflammatory, cancer and liver diseases, today announced financial results for the quarter ended September 30, 2021.
  • Corporate and Clinical Development Highlights Include:
    Completed Patient Enrollment in Phase III Psoriasis Study The Phase III Comfort study completed patient enrollment.
  • Financial income, net for the nine months ended September 30, 2021 was $0.31 million compared to financial expense, net of $0.22 million for the same period in 2020.
  • The Company's consolidated financial results for the nine months ended September 30, 2021 are presented in accordance with US GAAP Reporting Standards.

Peer-Reviewed Target RWE Study Finds Wide Variance in Nonalcoholic Steatohepatitis (NASH) Pathology Reporting

Retrieved on: 
Wednesday, November 3, 2021
Dyslipidemia, Science, MD, Liver disease, Biotechnology, University, Assistant, Real, University of North Carolina School of Law, Pharmacology, Pathology, Pragmatism, NAFLD, Target, Patient, Correlation and dependence, ALT, Liver biopsy, Biopsy, RWE, Alimentary Pharmacology & Therapeutics, Non-alcoholic fatty liver disease, Adult, Software, Collection, Chapel Hill, Vanderbilt University, Documentation, Hepatology, Solution, Fatty liver disease, Therapy, NASH, Division, Population, Associate, Iterative method, Medical device, Medicine, Medical imaging

Target RWE study analyzed 222 liver pathology reports from 38 sites and found that documentation is often inconsistent.

Key Points: 
  • Target RWE study analyzed 222 liver pathology reports from 38 sites and found that documentation is often inconsistent.
  • "The current lack of consistency is concerning in terms of patient assessment and translation of practice guidelines for this growing population.
  • The study analyzed 222 liver pathology reports from TARGET-NASH patients from 38 sites, including re-examination by a blinded central expert pathologist.
  • Target RWE is a health evidence solutions company that generates innovative real-world evidence (RWE) and provides scientific intelligence tools and solutions for pharmaceutical, biotechnology, and other healthcare partners.

Positive Data from Phase IIa Can-Fite NASH Study Published in Leading Peer Reviewed Scientific Journal

Retrieved on: 
Thursday, October 21, 2021
Software, Biotechnology, Pharmaceutical, Oncology, Health, Technology, Genetics, Clinical Trials, Woman, Phase, Melanoma, Cancer, Technology, HCC, Disease, Incidence, Prostate, Industry, Institute of Liver and Biliary Sciences, Drug development, NIH, Writing, TASE, Obesity, CANF, Patient, Psoriasis, Liver cancer, NYSE, Food, Erectile dysfunction, U.S. Securities and Exchange Commission, SEC, Hepatocellular carcinoma, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Non-alcoholic fatty liver disease, Forward-looking statement, Company, COVID-19, Multimedia, Gastroenterology, Fatty liver disease, Therapy, NASH, Risk, Population, Liver, Steatohepatitis, Colon, P-value, Alimentary Pharmacology & Therapeutics, Pharmaceutical industry, Medical device

View the full release here: https://www.businesswire.com/news/home/20211021005526/en/

Key Points: 
  • View the full release here: https://www.businesswire.com/news/home/20211021005526/en/
    Positive Data from Phase IIa Can-Fite NASH Study Published in Leading Peer Reviewed Scientific Journal (Photo: Business Wire)
    The article includes highlights from Can-Fites Phase IIa NASH study of Namodenoson which achieved its study endpoints including significant anti-steatotic, anti-fibrotic, and anti-inflammatory effects.
  • Namodenoson is advancing into a Phase IIb NASH trial which is expected to commence patient enrollment in Q4 2021.
  • Principal Investigator of the Phase IIa study, Prof. Rifaat Safadi, commented, The acceptance and publication of the article presenting our Phase IIa results in this prestigious journal demonstrates the high value of the data and the potential of Namodenoson as safe and effective treatment for NASH.
  • As of 2016, NASH was the leading cause for liver transplants among women and the second leading cause for liver transplants overall.